TABLE 1.
Patients demographics and clinical characteristics during hopitalization at wards.
| Non-AKI n = 71 | AKI n = 23 | p | |
|---|---|---|---|
| Age (years) | 47.1 ± 14.5 | 57.13 ± 18.6 | 0.01 |
| Male sex (%) | 46 (64.8) | 17 (74) | 0.42 |
| Creatinine at admission (mg/dl) | 0.81 ± 0.24 | 1.09 ±0.24 | 0.001 |
| Higher Creatinine (mg/dl) | 0.98 ± 0.6 | 2.15 ± 1.46 | <0.001 |
| Creatinine at discharge (mg/dl) | 0.74 ± 0.47 | 1.37 ± 0.86 | <0.001 |
| Comorbidities (%) | |||
| Hypertension | 20 (28.2) | 15 (65.2) | 0.001 |
| Diabetes | 17 (24) | 10 (43.5) | 0.07 |
| CKD | 4 (5.6) | 1 (4.3) | 0.81 |
| Cardiovascular disease | 8 (11.3) | 5 (21.7) | 0.20 |
| Cancer | 14 (19.7) | 2 (8.7) | 0.22 |
| Cause of hospitalization (%) | |||
| Infections | 16 (22.5) | 12 (50.0) | 0.02 |
| Cardiovascular | 5 (7) | 4 (16.6) | 0.20 |
| Surgery | 38 (53.5) | 5 (20.4) | 0.04 |
| Time of hospitalization (days) | 34.5 ± 13.8 | 33.6 ± 10.94 | 0.9 |
| Time of vancomycin use (days) | 14.7 ± 9.6 | 17.3 ± 7.04 | 0.24 |
| Vancomycin doses/day (g) | 2.5 ± 0.9 | 2.24 ± 1.1 | 0.48 |
| Vancomycin concentration T0-48 h (mg/L) | 14.5 ± 9.3 | 18.3 ± 15.1 | 0.15 |
| Vancomycin concentration T48-96 h (mg/L) | 15.4 ± 8.9 | 21.7 ± 9.7 | 0.006 |
| Vancomycin concentration T96-144 h (mg/L) | 17.1 ± 10.1 | 24.2 ± 19.1 | 0.03 |
| Vancomycin concentration T144-192 h (mg/L) | 16.5 ± 9.1 | 24.3 ± 7.7 | 0.003 |
| Vancomycin concentration T192-240 (mg/L) | 17.5 ± 9.6 | 28.4 ± 18.5 | 0.016 |
| Vancomycin concentration T240-288 h (mg/L) | 21.3 ± 16.6 | 32.4 ± 27.1 | 0.161 |
| Death (%) | 6 (8.4) | 2 (8.7) | 0.97 |
CKD, chronic kidney disease; T, time of vancomycin use.